(Sharecast News) - Truetide said on Wednesday that its wholly-owned subsidiary Paraytec had launched a focused development programme aimed at establishing a high-throughput, real-time fluorescent assay to study alpha-synuclein fibril formation, targeting a key bottleneck in Parkinson's disease drug discovery.
The AIM-traded firm, formerly known as Braveheart Investment Group, said Paraytec...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE